Premium Alternative Insight and Premium Journalism

Venture capital firms Bios Partners and Kairos Ventures own big stakes in Actuate Therapeutics, which has set the terms for its upcoming IPO.
The Latest
The multistrategy hedge fund’s equity strategy led the way last month, kicking in 5.2 percent to net returns.
This retailing giant enjoyed a surge of hedge fund buying in the first quarter.
After facing a challenging fundraising environment for the new fund in 2022, Mudrick has lowered its target.
It was feast or famine for most of David Einhorn’s largest longs last month.
A slew of new hedgies initiated positions in this semiconductor company.
The IPO market is starting to show signs of life — and health care is one of the most active sectors.
More firms initiated than sold off positions in 18 of the 20 most widely held stocks in the first quarter, according to SEI Novus.
More in Premium